Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy.
作者信息
Vanni Kathleen Mm, Patel Naomi J, DiIorio Michael, Kowalski Emily, Qian Grace, Cook Claire E, Ritter Susan Y, Wallace Zachary S, Sparks Jeffrey A
机构信息
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
出版信息
RMD Open. 2022 Feb;8(1). doi: 10.1136/rmdopen-2021-002082.
Abstract
摘要
相似文献
1
Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy.三剂新冠病毒mRNA疫苗接种后在系统性自身免疫性风湿病中出现的突破性感染：两例接受肿瘤坏死因子抑制剂单药治疗的患者
RMD Open. 2022 Feb;8(1). doi: 10.1136/rmdopen-2021-002082.
2
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对单剂SARS-CoV-2 mRNA疫苗的抗体反应。
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
3
Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.新冠病毒信使核糖核酸疫苗在使用肿瘤坏死因子抑制剂治疗的青少年特发性关节炎青少年中的免疫原性。
Ann Rheum Dis. 2022 Apr;81(4):592-593. doi: 10.1136/annrheumdis-2021-221607. Epub 2021 Nov 29.
4
Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study.系统性自身免疫性风湿病患者对 SARS-CoV-2 疫苗接种的反应取决于免疫抑制方案：一项匹配的前瞻性队列研究。
Ann Rheum Dis. 2022 Jul;81(7):1017-1022. doi: 10.1136/annrheumdis-2021-221788. Epub 2022 Mar 18.
5
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases.免疫介导的炎症性疾病患者对 SARS-CoV-2 mRNA 疫苗的免疫应答迅速减弱。
JCI Insight. 2022 Jun 8;7(11):e159721. doi: 10.1172/jci.insight.159721.
6
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.接种疫苗的系统性自身免疫性风湿病患者中新冠病毒突破性感染的临床特征与结局
Ann Rheum Dis. 2022 Feb;81(2):289-291. doi: 10.1136/annrheumdis-2021-221326. Epub 2021 Sep 6.
7
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间，接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
8
Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.利妥昔单抗治疗后时间对于风湿性疾病患者对 COVID-19 mRNA 疫苗产生体液免疫反应至关重要。
J Rheumatol. 2022 Jun;49(6):644-649. doi: 10.3899/jrheum.211152. Epub 2022 Mar 1.
9
Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.青少年和年轻成年人风湿性疾病患者 COVID-19 疫苗相关不良事件的早期经验：一项单中心研究。
Int J Rheum Dis. 2022 Mar;25(3):353-363. doi: 10.1111/1756-185X.14279. Epub 2022 Jan 3.
10
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.在一项单中心队列研究中，慢性炎症性疾病和免疫抑制治疗患者的抗 SARS-CoV-2 mRNA 疫苗的免疫原性和安全性。
Ann Rheum Dis. 2021 Oct;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272. Epub 2021 Mar 24.
引用本文的文献
1
Additional Reassuring Data for SARS-CoV-2 Vaccination in Immune-Mediated Inflammatory Diseases, but With a Catch.免疫介导性炎症疾病中接种新型冠状病毒疫苗的更多令人安心的数据，但有一个问题。
J Rheumatol. 2024 Apr 1;51(4):332-335. doi: 10.3899/jrheum.2024-0006.
2
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.接种过两剂和三剂疫苗的炎症性风湿病患者中 SARS-CoV-2 突破性感染的特征和结局。
RMD Open. 2023 Apr;9(2). doi: 10.1136/rmdopen-2023-002998.
3
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.COVID-19 患者中系统性自身免疫性风湿病的时间趋势：从第一波到最初的奥密克戎波。
Ann Rheum Dis. 2022 Dec;81(12):1742-1749. doi: 10.1136/ard-2022-222954. Epub 2022 Aug 9.
4
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron.系统性自身免疫性风湿病患者中 COVID-19 结局的时间趋势：从第一波疫情到奥密克戎毒株时期
medRxiv. 2022 Jun 20:2022.06.19.22276599. doi: 10.1101/2022.06.19.22276599.
5
COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases.COVID-19：未接种疫苗、接种 2 剂和 3 剂 SARS-CoV-2 疫苗的系统性自身免疫和自身炎症性风湿病患者的临床特征和结局。
J Autoimmun. 2022 Jul;131:102846. doi: 10.1016/j.jaut.2022.102846. Epub 2022 Jun 9.
本文引用的文献
1
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors.mRNA 疫苗接种者在接受肿瘤坏死因子-α 抑制剂治疗后血清中针对 SARS-CoV-2 B.1.617.2 德尔塔病毒的抗体活性降低。
Med. 2021 Dec 10;2(12):1327-1341.e4. doi: 10.1016/j.medj.2021.11.004. Epub 2021 Nov 18.
2
SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases.炎症性风湿性和肌肉骨骼疾病患者接种疫苗后感染新型冠状病毒2型
Ann Rheum Dis. 2022 Jan;81(1):145-150. doi: 10.1136/annrheumdis-2021-221217. Epub 2021 Sep 6.
3
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.接种疫苗的系统性自身免疫性风湿病患者中新冠病毒突破性感染的临床特征与结局
Ann Rheum Dis. 2022 Feb;81(2):289-291. doi: 10.1136/annrheumdis-2021-221326. Epub 2021 Sep 6.
4
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic.大流行 6 个月后患风湿性疾病患者的 2019 年冠状病毒病结局。
Ann Rheum Dis. 2021 May;80(5):660-666. doi: 10.1136/annrheumdis-2020-219279. Epub 2020 Nov 30.
Zotero 插件